drugset
drugset / Trial / NCT06240546

First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.

NCT06240546 ↗

Phase 1 Recruiting 102 enrolled Luye Pharma Group Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.

Timeline

Start
2024-03-12
Primary completion
2026-02
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject LPM6690176 Unknown 2 mg/m2 Oral
Subject LPM6690176 Unknown 4 mg/m2 Oral
Subject LPM6690176 Unknown 8 mg/m2 Oral
Subject LPM6690176 Unknown 16 mg/m2 Oral
Subject LPM6690176 Unknown 24 mg/m2 Oral
Subject LPM6690176 Unknown 36 mg/m2 Oral
Subject LPM6690176 Unknown 48 mg/m2 Oral

Indications

neoplastic disease or syndrome